The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 0.79 — distress zone — historically elevated failure riskWatch
Where the revenue comes from
Fiscal 2025, as Rallybio Corp reports it. History and quarterly detail are in the app.
- Collaboration and license revenue$858K
- License$800K
Leadership changes
From Rallybio Corp's own filings, the day they're filed.
- Steven Ryder · Chief Medical Officer · departureeff. 2026-03-31
- Martin Mackay · Chairman · departureeff. 2024-12-31
- Stephen Uden · Chief Operating Officer · appointmenteff. 2023-08-01
Latest filings
- 8-K · Company announcement2026-06-01
- 10-Q · Quarterly report2026-05-13
- 8-K · Company announcement2026-05-04
- 8-K · Company announcement2026-03-31
- 10-K · Annual report2026-03-16
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Rallybio Corp, every answer cited🔒
- The Intelligence Brief — added when Rallybio Corp's brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.